Lifeboat Foundation

Is a Gerontologist and Clinical Social Worker on a mission to rethink aging, longevity & mental health.

Ms. Anderson was also the former lead singer of the American Rock group, The Donnas (https://en.wikipedia.org/wiki/The_Donnas), where she was the lead vocalist for 20 years, performing throughout the U.S., as well as internationally, and had performances / appearances on major network shows including Saturday Night Live, David Letterman and Late Night with Conan O’Brien.

Continue reading “Brett Anderson, MSG, MSW — Journey From Rock Musician To Rethinking Aging, Longevity & Mental Health” »

On December 6–7, 2022, the Buck Institute for Research on Aging will be hosting the Longevity Summit 2022. Lifespan.io is pleased to announce that we are an official media partner for this upcoming conference.

The Summit will see many of the leading experts in the field coming together in the grounds of the architecturally distinct Buck Institute. It is being framed as a peer-to-peer learning experience aiming to unite longevity entrepreneurs, pharma and biotech companies, investors, researchers, and government organizations.

Here’s what the organizers had to say about the event:

Dr Brian Kennedy explains why verifying longevity interventions work is key and why the transition to human trials is so important.

Brian Kennedy is one of the busiest people in the longevity business, with fingers in many of the most interesting antiaging pies. He was at the Longevity Investors Conference recently, discussing some of the latest discoveries in longevity research and giving a longevity industry overview.

Continue reading “Dr Brian Kennedy — validating aging interventions and why rapamycin is the gold standard” »

Dr Charles Brenner on the longevity understanding disconnect, the best interventions for longevity, and the NR trials he’d like to see.

The Longevity Investors Conference is a key event for those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. The world’s leading and most private longevity-focused investors-only conference, LIC attracts some of the most prominent thought leaders.

Continue reading “Dr Charles Brenner: longevity is not a simple engineering problem” »

Regenerative medicine company Frequency Therapeutics is developing new drugs that activate our innate abilities to restore function and reverse degenerative diseases. The company is working on small molecules that selectively activate progenitor cells already present within our bodies to create healthy, functional tissues. Frequency’s initial focus is on hearing loss and multiple sclerosis, and the company has just completed enrolment of a Phase 2b trial in adults with acquired sensorineural hearing loss (SNHL).

Longevity. Technology: Frequency is focused on progenitor cells, which are like stem cells but can only make cells that belong to the same tissue or organ. While progenitor cells remain active in some of our organs and tissues, they can become dormant in others. Frequency’s small molecules are designed to selectively target and induce dormant progenitor cells to create specific cell types to restore tissue structure and function. We caught up with Frequency’s Chief Scientific Officer Dr Chris Loose to learn more.

Nasdaq-listed Frequency was founded in 2014, licensing technology developed by professors Robert Langer from MIT and Jeffrey Karp from Harvard Medical School.

Dr talks taking hardcore science to market without biotech approval risk and the catalyst that is translational research.

We were lucky enough to attend the Longevity Investors Conference last month; this key event attracts those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. To put it succinctly, as MIT Tech Review did recently, LIC “brings academic scientists and biotech companies together with deep-pocketed investors. We’re talking millionaires and billionaires.”

Continue reading “Tobias Reichmuth — the longevity market starts now” »

A multinational team headed by University College London scientists has discovered a new mechanism that slows down and maybe even prevents the normal aging of immune cells, one of the nine “hallmarks of aging.”

The discovery in-vitro (cells) and validated in mice was “unexpected,” according to the researchers, who believe harnessing the mechanism might extend the life of the immune system, enabling people to live healthier and longer lives, and would also have therapeutic use for diseases such as cancer and dementia. Their findings were recently published in the journal Nature Cell Biology.

Explaining the study, lead author, Dr. Alessio Lanna, Honorary Professor at UCL Division of Medicine, said: Immune cells are on constant high-alert, always ready to fight pathogens. To be effective they also must persist for decades in the body – but the strategies employed to execute this life-long protection are largely unknown.

New foundation aims for scientific and rhetorical value – and to run the debug cycle for longevity research.

The Longevity Investors Conference is quickly turning into one of the highlights in the longevity calendar, and we were delighted to be able to interview some of the speakers in a few ‘backstage’ moments.

Continue reading “Aubrey de Grey on longevity at scale” »

Dr. Michael Rose is an evolutionary biologist and authority in gerontology. His many years of research and keen insight establish unique methods to frame the problems of aging. Michael made scientific history with experiments manipulating the life spans of fruit flies. As a pragmatist, Michael sees beyond today’s quick fixes to examine what could be the most important changes in the longevity industry to slow down and stop aging. His view is that genomics in conjunction with machine learning is the future of longevity.